Early versus late intensification of glucose-lowering therapy in patients with type 2 diabetes: results from the DISCOVER study

To assess the effects of glycated haemoglobin (HbA1c) levels at time of glucose-lowering treatment intensification in DISCOVER, a global observational study of patients with type 2 diabetes (T2D) initiating second-line therapy. Outcomes of interest were glycaemic control, hypoglycaemia, and need for further intensification during 3 years of follow-up.

Source: Diabetes Research and Clinical Practice - July 9, 2021 Category: Endocrinology Authors: Linong Ji, Fabrice Bonnet, Hungta Chen, Andrew Cooper, Niklas Hammar, Paul Leigh, Gabriela Luporini Saraiva, Larisa Ramirez, Jes ús Medina, Antonio Nicolucci, Wolfgang Rathmann, Marina V Shestakova, Filip Surmont, Fengming Tang, Hirotaka Watada, on behal Source Type: research